The 0.3% foam formulation of roflumilast was previously approved for the treatment of seborrheic dermatitis in adults and ...

Roflumilast foam, 0.3%, proved to be a simplified treatment regimen with high efficacy for patients with scalp and body ...

Topical roflumilast 0.3% cream has been approved by the FDA to treat plaque psoriasis in patients 12 years and older since ...

The approval was supported by data from 2 randomized, double-blind, vehicle-controlled trials that included 736 patients aged 12 years and older with mild to severe plaque psoriasis of the scalp and ...

Scalp psoriasis often presents with ... reduction in the Scalp Itch Numeric Rating Scale at week eight compared to 30.3% in the placebo group. Treatment-emergent adverse events occurred more ...

ZORYVE foam is a once-daily, steroid-free topical and is now widely available as a treatment for plaque psoriasis ... from baseline in Scalp Itch-Numeric Rating Scale (SI-NRS).

ZORYVE foam is a once-daily, steroid-free topical and is now widely available as a treatment for plaque psoriasis. Nearly 9 million ... by a ≥ 4-point change from baseline in Scalp Itch-Numeric Rating ...

may improve treatment outcomes by increasing adherence. Roflumilast foam, 0.3% (Zoryve) used once-daily significantly improved itch and other symptoms of plaque psoriasis of the scalp and body ...